You are viewing the site in preview mode
Skip to main content
|
Cell line
|
ATCC
|
Sub-type
|
Markers [46]
|
EZH2
|
H3K27me3
|
|---|
|
MCF7
|
HTB-22
|
Luminal A
|
ER+, PR+
|
Elevateda,b,c [59,60,61]
|
Elevateda [57, 60]
|
|
BT-474
|
HTB-20
|
Luminal B
|
ER+, PR+, HER2+
|
Elevatedc [62]
|
Elevatedd [57]
|
|
BT-549
|
HTB-122
|
Basal B, claudin-low
|
ER-, PR-, TP53M
|
Elevatedc [8]
|
Elevatedd [57]
|
|
MCF10A
|
CRL-10317
|
Non-invasive/ Basal B
|
ER-, PR-
|
n/a
|
n/a
|
- ATCC American Tissue Culture Center ID. Molecular subtype and marker expression status are from Neve et al. 2006 [46]: Estrogen receptor presence or absence (ER+/−), Progesterone receptor presence or absence (PR+/−), HER2 overexpression (HER2+), and TP53 mutation (TP53M). EZH2 and H3K27me3 were shown to be elevated compared to non-metastatic fibroblasts (a) [60], LNCaP (b) [59], MCF10A (c) [8, 61, 62], and HMEC (d)
